Trytosaveabit commented on a stock · 10 hours ago

Update

$Nkarta(NKTX.US)$ Nkarta Has Initiated An Investigator-sponsored Trial Of NKX019, A Cd19-directed Chimeric Antigen Receptor NK-cell Therapy For Systemic Lupus Erythematosus. In June 2024, Nkarta Initiated Ntrust-1 Phase 1 Trial Of NKX019 For Lupus Nephritis

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

1185 Views

Comment

Trytosaveabit

2536Followers

28Following

34KVisitors